(Q38199178)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

meta-analysis

0 references

title

Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Mona Fouad

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

26 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

751-760

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894465

10.1586/14737140.2014.894465

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24666215%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference